RT @aburnett_PharmD: @ImBigPharma @beaverspharmd @AnticoagForum @GBarnesMD @AAllenPharmD @accpcardprn Per protocol dosing in ARISTOTLE to a…
RT @aburnett_PharmD: @ImBigPharma @beaverspharmd @AnticoagForum @GBarnesMD @AAllenPharmD @accpcardprn Per protocol dosing in ARISTOTLE to a…
RT @aburnett_PharmD: @ImBigPharma @beaverspharmd @AnticoagForum @GBarnesMD @AAllenPharmD @accpcardprn Per protocol dosing in ARISTOTLE to a…
RT @aburnett_PharmD: @ImBigPharma @beaverspharmd @AnticoagForum @GBarnesMD @AAllenPharmD @accpcardprn Per protocol dosing in ARISTOTLE to a…
@ImBigPharma @beaverspharmd @AnticoagForum @GBarnesMD @AAllenPharmD @accpcardprn Per protocol dosing in ARISTOTLE to account for frailty & ⬆️ exposure (~5%of pts). Recent analysis shows appropriately ⬇️ dose using ABC 2/3 retains benefits observed in t
加えて、減量基準に2つ以上該当する患者において、ワルファリンに対するアピキサバン減量の効果は、脳卒中/全身性塞栓症、大出血および死亡の減少において標準用量と一致していた。
RT @pinacol: 【事後解析: ARISTOTLE】心房細動患者において、減量(2.5mgx2)群は標準用量(5mgx2)群よりもアピキサバンのより低い曝露を示した。減量基準に2つ以上該当する患者は、標準用量の患者と比較して、脳卒中/全身性塞栓症、大出血および全原因死亡…
【事後解析: ARISTOTLE】心房細動患者において、減量(2.5mgx2)群は標準用量(5mgx2)群よりもアピキサバンのより低い曝露を示した。減量基準に2つ以上該当する患者は、標準用量の患者と比較して、脳卒中/全身性塞栓症、大出血および全原因死亡のリスクが高かった。 https://t.co/IUeElljxm7
Lower doses (2.5 mg bid) of apixaban associated with lower drug concentrations (vs 5 mg bid) but consistent with warfarin for coagulation biomarkers and clinical outcomes. #AtrialFibrillation #StrokePrevention #Anticoagulation #DOACs #Apixaban https://t.
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial https://t.co/U2qASA0k7l
RT @JACCJournals: In older patients with #CKD and low body weight, when you give lower dose apixiban, do you feel confident in #stroke redu…
RT @JACCJournals: In older patients with #CKD and low body weight, when you give lower dose apixiban, do you feel confident in #stroke redu…
RT @JACCJournals: In older patients with #CKD and low body weight, when you give lower dose apixiban, do you feel confident in #stroke redu…
In older patients with #CKD and low body weight, when you give lower dose apixiban, do you feel confident in #stroke reduction? The ARISTOLE study investigates the effects of apixaban dose adjustment clinical and pharmacological outcomes: https://t.co/tsyE
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
Oh come on... apiXAban... it’s a Xa inhibitor. Like EdoXAban, RivaroXAban. Not you JACC, not you...
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
RT @JACCJournals: Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @Mic…
Is lowering the typical dose of apixiban effective and safe in #AFib patients who meet criteria for lower dose? Drs. @MichelZedBay, @gabrielsteg et al. share their findings with results from the ARISTOTLE trial in a new #JACC. https://t.co/tsyEINDT3m https
RT @docjohanne: Well done Michel !
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
Well done Michel !
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
Congrats Michel ! This is a great work !
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
RT @JTLLERGO: ⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or sy…
⚠️ Importance correct Apixaban dose adjustment to 2.5 mg: 📍reductions in D-dimers and PF1+2 📍and reductions in stroke or systemic embolism, major bleeding, and death were consistent with those observed in standard-dose https://t.co/LxHRnvauZR @secardiol
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
RT @MichelZedBay: Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concom…
Check out our work on #apixaban dose adjustment in #aristotle. Individuals with >= 2 dose adjustment criteria : 1. concomittant higher risk of stroke and bleeding than standard population 2. Less time in therapeutic range and more time INR>3 with war